MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

Top advisers to Robert F. Kennedy Jr. are battling over how aggressively to target vaccines during his first days as the ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Co., Inc. (NYSE:MRK) and Eisai Co., Ltd. (TYO:4523) have announced the latest outcomes from their Phase 3 LEAP-015 trial, ...

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.

We recently compiled a list of the Billionaire Prem Watsa’s Top 15 Long-Term Stock Picks. In this article, we are going to ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

Merck KGaA (Merck) and Opentrons Labworks have announced a partnership to automate assay kits on a ‘custom’ Opentrons Flex ...

A recent health news roundup explores legal, financial, and strategic developments. Highlights include Robert F. Kennedy ...